Astrazeneca, Daiichi Sankyo's Breast Cancer Drug Approved in China
MT Newswires Live
Oct 08
AstraZeneca (AZN) and Daiichi Sankyo's breast cancer therapy, Datroway, was approved in China, Daiichi Sankyo said Thursday.
The company said the approval was based on the phase 3 trial in which Datroway extended median overall survival to 23.7 months from 18.7 months with chemotherapy.
The treatment also reduced the risk of disease progression or death by 43%, with median progression-free survival of 10.8 months versus 5.6 months for chemotherapy, the company said.
Datroway is being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo, it added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.